Dapansutrile

N/A

Report date: 2026/04/03 20:03:44
NME

Base Information

Drug NameDapansutrile
Drug Alias Namedapansutrilum达泮舒腈dapansutrilodapansutrileOLT-1177
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInflammasomes inhibitorsNACHT, LRR and PYD domains-containing protein 3 inhibitorsInterleukins inhibitors
TargetsInflammasomesInterleukinsNACHT, LRR and PYD domains-containing protein 3
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)PainCytokine Release Syndrome +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands +[9] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesOlatec Therapeutics Llc
China Registration ClassN/A

Develop Information

Active CompaniesOlatec Therapeutics LlcUniversity Of Virginia
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Myocardial InfarctionParkinson Disease +[8] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)PainCytokine Release Syndrome +[6] 

Other Information

ATC CodeN/A
Related LinksN/A